International Regulation of Hazardous and Biomedical Waste Shipments under the Basel Convention

International Regulation of Hazardous and Biomedical Waste Shipments under the Basel Convention

A Study of Transboundary Movement Controls, Judicial Precedent, and Enforcement Gaps in the Global Waste Trade

Part I: Abstract / Introduction

Few international treaties owe their existence so directly to a scandal as the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal. It emerged in 1989 after a string of incidents in which toxic waste from wealthier nations turned up in developing countries, sometimes labelled as fertiliser, sometimes as raw material for recycling, and sometimes not labelled at all. Today the Convention binds 187 Parties and reaches far beyond its original targets — used batteries, industrial sludge, and, importantly for this article, clinical and pharmaceutical waste of the kind hospitals generate every day. What follows traces the legal machinery built around such shipments: the prior informed consent procedure that governs every export, the environmentally sound management standard Parties are meant to uphold, and the specific place biomedical waste occupies under Annex I. It then turns to how courts, the Indian Supreme Court above all, have actually interpreted and enforced these obligations on the ground, before closing with an honest look at where the framework still falls short more than three decades on.

Part II: Background and Legal Framework

The Convention was negotiated under the United Nations Environment Programme’s auspices after a run of incidents in the 1980s in which European and North American waste brokers shipped toxic residues to West Africa and other developing regions, frequently mislabelled to disguise what was actually inside the containers. Two ideas sit underneath everything the Convention does: waste generation and its movement across borders should be kept to a minimum, and whatever waste does exist should be managed responsibly and disposed of as close as possible to where it was produced.

Article 6 sets out the mechanism that makes this workable in practice — the Prior Informed Consent, or PIC, procedure. Before exporting hazardous waste, a Party must notify the importing state’s competent authority in detail: what the waste contains, how much of it there is, and how it will be disposed of. Nothing can move until the importing state agrees in writing. Skip that step, or ship to a country that has not joined the Convention without a special arrangement in place, and the shipment counts as illegal traffic. Article 4 goes further still, requiring every Party to make such conduct a criminal offence under its own domestic law.

For anyone working on healthcare waste specifically, Annex I is where the Convention becomes directly relevant. It lists clinical waste from hospitals, medical centres, and clinics as waste stream Y1, and pharmaceutical products and drugs as Y3. That means an untreated batch of incineration ash, a shipment of expired medicines, or infectious clinical residue crossing a border all trigger the full PIC procedure — unless, under Article 11, the two countries involved have already agreed to a bilateral standard that is at least as protective.

Article 9 fills in what happens when things go wrong. If a shipment is carried out without proper notification, without the consent of the states involved, or through outright fraud, it is treated as illegal traffic, and the exporting state must ensure the waste is either re-imported by the exporter or disposed of safely, typically within thirty days of being notified. In practice, this re-import duty is often the only remedy that actually works once contaminated or mislabelled biomedical waste has already crossed a border — prosecuting the original exporter, though technically required under Article 4, tends to run into jurisdictional and evidentiary walls the moment the waste has left the exporting country’s territory.

The Ban Amendment and Its Long Road to Force

Not everyone thought consent-based rules went far enough. Developing countries and much of the environmental community wanted an outright prohibition, and at the Third Conference of the Parties in 1995 they got one, at least on paper: Decision III/1, the Ban Amendment, added a new Annex VII listing OECD, EU, and Liechtenstein Parties who would be barred from exporting hazardous waste — for any reason, including recycling — to everyone else. The catch was procedural. Amending the Convention required ratification by three-quarters of the Parties who had been present at adoption, and that threshold was not reached until 2019, meaning the Ban Amendment did not actually enter into force until 5 December 2019 — almost a quarter of a century after it was first agreed. It is a useful reminder that political agreement on paper and a treaty actually taking legal effect are two very different things.

Later Amendments Expanding Scope

• 2019 Plastic Waste Amendments (effective 1 January 2021): brought contaminated and mixed plastic waste under the PIC procedure, closing a loophole that had allowed unsorted plastic scrap to move across borders without prior consent.
• 2022 E-Waste Amendments (effective 1 January 2025): extended Prior Informed Consent to virtually all electronic and electrical waste, addressing the rapid growth of transboundary e-waste dumping.
• Ongoing guidance on healthcare waste: the Secretariat’s technical guidelines on Y1 and Y3 waste streams require generating facilities to appoint a designated waste management officer and to minimise waste at source before any thought of export or disposal abroad.

India’s Domestic Implementation

India ratified the Convention in 1992, and gives it domestic teeth mainly through the Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016, framed under the Environment (Protection) Act, 1986. The Ministry of Environment, Forest and Climate Change acts as the nodal authority for import and export consents; import of hazardous waste for disposal is banned outright, and import for recycling or recovery is allowed only under fairly strict conditions and prior authorisation. In practice, biomedical waste imports are almost never permitted — India already struggles to treat what it generates domestically, let alone what anyone else might want to send its way.

Part III: Main Analysis and Case Studies

If you want to see how courts have actually applied these rules, ship-breaking is where the litigation has been thickest. End-of-life vessels arriving at South Asian breaking yards routinely carry asbestos, waste oil, and PCBs, and disputes over their disposal have produced some of the most detailed judicial reasoning on the Basel Convention anywhere in the world. These cases are not about biomedical waste directly, but the reasoning courts developed while sorting through them has gone on to shape how every category of Annex I waste, clinical and pharmaceutical residue included, gets treated once a dispute reaches a courtroom.

Research Foundation for Science, Technology and Natural Resource Policy v. Union of India

This public interest litigation started in 1995 and, by the time it wound down through phases in the early 2000s, had become the closest thing India has to a definitive statement on hazardous waste law. Acting on the petitioner’s submissions, the Supreme Court ordered the Union Government to ban the import of hazardous waste and to bring the old Hazardous Wastes (Management and Handling) Rules in line with the Basel Convention — and it grounded that obligation directly in the Constitution, invoking Article 21’s right to life alongside the State’s duties under Articles 47 and 48A to raise public health standards and protect the environment. Along the way, the case also took up groundwater contamination in Gujarat’s Vapi industrial belt, a reminder that transboundary waste problems rarely arrive in isolation; they tend to compound whatever domestic pollution is already there. One figure from the judgment sticks: India was generating several million tonnes of hazardous waste a year against a treatment infrastructure of only a handful of working disposal facilities. The lesson for biomedical waste specifically is straightforward — a country does not need to import much hazardous waste at all for the Convention’s environmentally sound management standard to be breached, because domestic generation on its own can overwhelm whatever capacity exists.

The Blue Lady Litigation (2007)

The tanker Blue Lady sat idle at a Gujarat port for over a year, loaded with asbestos and other hazardous materials, while its owners and Indian authorities argued over who was responsible for decontaminating and disposing of it. When the Supreme Court finally ruled in September 2007, it set out guidelines requiring decontamination before any vessel could even arrive for breaking, and it put State Pollution Control Boards, the Customs Department, the National Institute of Occupational Health, and the Atomic Energy Regulatory Board in charge of jointly supervising the dismantling process from then on. What is notable about the ruling is how comfortable the Court was reading Basel-consistent obligations into everyday regulatory practice, even though Parliament had not gotten around to passing precise legislation for ship-generated waste.

M.V. Oriental Nicety (the Former Exxon Valdez)

By 2012, the vessel at the centre of the dispute was the M.V. Oriental Nicety — better known under its earlier name, the Exxon Valdez, the tanker behind the infamous 1989 Alaskan oil spill. The Supreme Court allowed it to be dismantled at the Alang yard, but attached a condition that turned out to matter far more than the case itself: no future vessel would be permitted to dock for dismantling without prior environmental clearance and Basel-compliant decontamination. A one-time permission had, in effect, become a standing rule, folding the Convention’s environmentally sound management standard into the ordinary licensing process for India’s entire ship-breaking industry.

Conti 11. Container Schiffahrt (Court of Justice of the European Union, 2025)

Not every relevant case involves a vessel headed for scrapping. In 2025, the CJEU’s Grand Chamber had to work out what counts as “waste” under the EU’s Waste Shipment Regulation — itself built to implement the Basel Convention — after the container ship MSC Flaminia suffered an explosion and fire on the high seas. The question was whether the fire-damaged cargo residue, once offloaded at a safe port, amounted to a shipment of waste triggering the Regulation’s notification and consent requirements. The Court said yes: Basel-derived shipment controls apply even to waste that arises unexpectedly during a voyage, not just waste that was deliberately loaded for export. That distinction matters well beyond shipping accidents — it is directly relevant to any future dispute over biomedical or pharmaceutical material that is damaged or generated unexpectedly in transit.

Taken together, these four cases trace one continuous arc. Courts, national and regional alike, have kept stepping in to fill the gaps the Convention’s own consent-based system leaves open — sometimes by grounding hazardous waste obligations in constitutional rights, sometimes by turning a single permission into a lasting licensing condition, sometimes by extending shipment controls to waste nobody planned to export in the first place. What none of them settles is the deeper definitional argument over exactly when an end-of-life vessel, or a damaged cargo residue, first becomes “waste” under the Convention. That question is still open internationally, and it keeps producing different answers in different courtrooms.

Part IV: Critical Analysis and Evaluation

The Convention has been ratified almost universally and its annexes keep expanding, yet three weaknesses have proven stubbornly resistant to reform. The most visible is the ship-recycling loophole that the Blue Lady and Oriental Nicety litigation exposed but never fully closed. Shipowning states still disagree over the precise moment a vessel becomes “waste” — is it the instant a shipowner decides to send it for scrapping, or only once it physically arrives at a breaking yard? That disagreement is not academic. It lets vessels change flag or ownership mid-voyage specifically to dodge Basel obligations, and the 2025 CJEU ruling, useful as it is, only narrows the gap for shipments with an EU connection. Nothing binding exists at the level of the Convention itself.

A second, less dramatic but arguably more consequential problem is the mismatch in enforcement capacity between exporting and importing states. Authorities in wealthier exporting countries can generally check a shipment’s declared contents before it leaves port. Many importing states cannot do the same on arrival. India is a case in point: despite the Vapi and Alang litigation, port-side inspection infrastructure remains thin, and that asymmetry is precisely what allows mislabelled biomedical or industrial waste to slip through even when the exporting state has, on paper, done everything the Prior Informed Consent procedure requires.

Biomedical waste also carries a risk the Convention’s drafters do not seem to have fully anticipated: it does not keep. Infectious clinical waste grows more dangerous the longer it sits untreated, but the PIC procedure was built with industrial and chemical waste in mind, and it has no expedited track for anything urgent. That gap showed up clearly during the COVID-19 pandemic, when several countries suddenly needed to move pandemic-related medical waste across borders simply because domestic incineration capacity had run out. Lacking any emergency consent pathway, governments fell back on ad hoc bilateral deals rather than anything resembling a coordinated international response.

There is also a quieter, structural problem underneath all of this: the Convention largely polices itself through self-reporting. Its own Implementation and Compliance Committee can only act once a matter is referred to it, and it has no independent power to investigate or sanction — nothing like the WTO’s dispute settlement machinery. For biomedical waste specifically, where illegal shipments are routinely disguised as recyclable plastic or scrap metal, this reliance on voluntary reporting means the Secretariat’s official statistics are almost certainly an undercount of what is actually moving across borders.

None of this points to a single fix. A workable reform agenda would need to include a binding, Basel-level clarification of when an end-of-life vessel counts as waste; a capacity-building fund — financed mainly by the wealthier Annex VII exporting states — to strengthen port-side verification in importing countries; and a fast-track consent mechanism reserved for Y1 and Y3 biomedical and pharmaceutical waste, so that genuinely urgent shipments do not have to choose between sitting untreated and being pushed through informal channels.

Part V: Conclusion

It has been more than three decades since the Basel Convention was adopted, and in that time it has grown from a narrow response to toxic dumping scandals into a genuinely comprehensive regime covering plastics, e-waste, and biomedical residue alike. What is perhaps most striking, looking back over the cases discussed here, is how much of the real work has been done by domestic courts rather than the treaty text itself. The Indian judiciary’s sustained engagement — from the constitutional grounding the Research Foundation litigation gave to hazardous waste obligations, through to the Blue Lady and Oriental Nicety orders that turned one-off permissions into standing rules — shows that an international treaty can be made to function even where national legislation never quite catches up. But the gaps that remain are real ones: the ship-recycling definitional dispute is still unresolved, enforcement capacity between exporting and importing states remains lopsided, and there is still no expedited route for infectious biomedical waste that genuinely cannot wait. If the Convention’s next phase of reform has a single lesson to take from all this, it is probably that expanding its substantive scope further will matter less than finally closing the practical gaps that let hazardous and biomedical waste continue slipping across borders unchecked.

References and Citations

Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal, 1989, arts. 1, 4, 6, 11; Annexes I, VII, VIII, IX.

Ban Amendment to the Basel Convention, Decision III/1 (1995), entered into force 5 December 2019.

Basel Convention Secretariat, Amendments to Annexes II, VIII and IX (Plastic Waste), adopted at COP-14 (2019), effective 1 January 2021.

Basel Convention Secretariat, Amendments Extending PIC to E-Waste, adopted at COP-15 (2022), effective 1 January 2025.

UNECE/Basel Convention Secretariat, Factsheet on Healthcare or Medical Waste (Y1; Y3), UNEP/CHW publication series.

Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016 (India).

Research Foundation for Science, Technology and Natural Resource Policy v. Union of India, Supreme Court of India (public interest litigation, orders 1997–2003).

Supreme Court of India, order on the Blue Lady ship-breaking dispute, Alang, Gujarat (September 2007), as reported by Down To Earth.

Supreme Court of India, order permitting dismantling of M.V. Oriental Nicety (formerly Exxon Valdez), Alang (2012), as reported by Deccan Herald.

Land Niedersachsen v. Conti 11. Container Schiffahrts-GmbH & Co. KG MS MSC Flaminia, Case C-188/23, Court of Justice of the European Union, Grand Chamber (21 January 2025).

IISD Earth Negotiations Bulletin, “Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and their Disposal” (summary and history).

FAQ

1. What is the Basel Convention?
It’s a 1989 international treaty that controls how hazardous waste — including biomedical and pharmaceutical waste — moves across borders. It requires exporting countries to get the importing country’s written consent before shipping such waste.

2. Does the Basel Convention cover hospital waste?
Yes. Clinical waste from hospitals is listed as category Y1, and pharmaceutical products/drugs as Y3, under Annex I. Any cross-border shipment of these triggers the Convention’s consent procedure.

3. What is the “Ban Amendment,” and is it in force?
It’s a 1995 addition that fully bans wealthier (OECD/EU) countries from exporting hazardous waste to other countries, even for recycling. It only entered into force in December 2019 — nearly 25 years after it was agreed — because it needed a three-fourths ratification threshold.

4. How does India implement the Convention domestically?
Mainly through the Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016. The Ministry of Environment, Forest and Climate Change handles import/export consents, and import of hazardous waste for disposal is banned outright.